Every round on record, with the sources behind each and the investors on them.
A provider of first-in-class disease-modifying therapies designed to restore vascular integrity
rougetx.comLinkedInNaarden, the NetherlandsBiotech
14 sources · checked 2 times, last 19h ago
The Angelini Ventures release headline calls EIB a co-lead, but RougeTx’s release describes EIB/Aurea as support; the company release controls.
| Round | Amount | Announced | Lead | Buzz |
|---|---|---|---|---|
| Series A | $58M | 2026-10-06 | Angelini Ventures, BioGeneration Ventures, Kurma Partners | 9 outlets. #31 in Trending |
14 sources · checked 2 times, last 19h ago [ VERIFIED · CORRECTED ] read against 4 of 14 sources
The Angelini Ventures release headline calls EIB a co-lead, but RougeTx’s release describes EIB/Aurea as support; the company release controls. | ||||
HHT affects about 1.4 million people worldwide, causes recurrent bleeding and potentially life-threatening arteriovenous malformations, and has no approved therapy, leaving patients reliant on supportive care and off-label treatments. RougeTx’s $58 million Series A is intended to move its once-daily oral lead program RTX-001 toward first-in-human development and support expansion of its periSCOPE pipeline into other diseases driven by vascular instability.
Also named as backers in company research: Aurea